We bring the lab to the patient
Traction
QuantiLight began as a research project in 2022 at the Max Planck Institute for Medical Research in Heidelberg, focusing on rapid, at-home therapeutic drug monitoring.
In Q1 2023, we secured public funding through the German EXIST-Forschungstransfer program, which supported the development of our prototypes. By Q4 2024, Prototype 1 was finalised and tested with patients in real-world settings, demonstrating the feasibility of our approach. Prototype 2 was successfully validated in Q3 2025, marking a key step toward product development.
The company was officially incorporated as QuantiLight GmbH in Q2 2025. We are now raising a seed round to finalize our commercial platform, advance clinical trials, and scale our team.
We have been accepted into the Mayo Clinic Innovation Exchange, the Life science accelerator Baden Württemberg, 4C Accelerator - Medical Innovations Incubator, and MAX!mize.
We are the missing diagnostic layer in the shift to real-time, decentralized care.
We are tackling the significant burden and cost of frequent blood testing for chronic patients and their caregivers. We are first focusing on therapeutic drug monitoring for organ transplant recipients, as well as kidney and liver function biomarkers.
The Technology
Our patented sensors are capable of quantifying biomarkers and drug concentrations with a very low limit of detection in complex matrices. These sensors are designed to emit light that changes color in response to the changing concentration of the biomarker. With high reproducibility and specificity, even at very low analyte concentrations (nanomolar) they can be easily detected using simple equipment such as a digital camera.
Bioluminescent Sensors
Our sensors find direct application in the diagnostic field, specifically for at-home monitoring. The test kit provides quantitative results for a patient’s drug levels within just 15 minutes. Thanks to these features, our rapid, affordable, quantitative and user-friendly home self-test can significantly reduce both time-to-result and costs compared to the Standard of Care.
Application in Diagnostics
Key publications underlying our technology:
-
Griss et al., 2014. Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring. Nat Chem Biol. Link
-
Yu et al., 2018. Semisynthetic sensor proteins enable metabolic assays at the point of care. Science. Link
-
Yu et al., 2019. A biosensor for measuring NAD+ levels at the point of care. Nat Metab. Link
HIGH
Receptor is occupied by the molecule, light turns blue
LOW
Receptor is free, light turns red
Bioluminescent sensors, light‐emitting biological reactions that transduces the presence of a target analyte into a measurable glow. Our bioluminescent sensor technology quantifies a broad range of biomarker families, including small molecule drugs, electrolytes, proteins, enzyme activities, amino acids, and metabolites.
Our technology.
Patented Bioluminescent Sensor Platform: Precise, Modular, Scalable.
Our self-test cartridge, read by a portable external reader, turns days of waiting for lab results into results in just 15 minutes from a simple fingerprick at home, delivering laboratory-grade accuracy.
One drop of blood (5 μl) from a finger prick is applied on the QuantiLight test cartridge. Its design dilutes the blood in order to be analyzed.
Test Cartridge
After inserting the test chip, the hand-held reader analyzes the blood sample with our proprietary and patented technology. Results are sent to the mobile application via Bluetooth.
Reader
Within minutes patients see the current drug concentration and can adapt accordingly with their doctor’s feedback. Communication and historical data supplement the patient benefit.
Mobile App
QuantiLight in Use
23 M
patients globally with the need for TDM
66%
of tests can be done from home
104 km
average commute per test
64%
saving potential for healthcare systems
Meet our Team
Rooted in the Department of Chemical Biology at the Max Planck Institute for Medical Research, our team combines deep technological understanding with practical execution of bringing innovations to where they matter most - the patients.
Our supporting Network
Contact us
We are looking for contacts with healthcare professionals, partners and investors.